Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa
Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced that the first patient has been dosed in its ongoing Phase 1/2 clinical study evaluating OCT-980, an investigational oral small molecule for the treatment of rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP).
Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments
Octant, Inc. (“Octant” or the “Company”), a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseases, today announced an $80 million Series B financing round led by Catalio Capital Management (“Catalio”), established a Deep Mutational Scanning (“DMS”) biopharma partnership with Bristol Myers Squibb, and appointed biotech industry veteran Dean “Rick” Artis as its first Chief Scientific Officer and renowned scientist Feng Zhang to its Scientific Advisory Board.
